Aravive Inc (ARAV) Stock Fundamental Analysis

NASDAQ:ARAV • US03890D1081

0.0401 USD
-0.01 (-13.39%)
At close: Jan 26, 2024
0.042 USD
+0 (+4.74%)
After Hours: 1/26/2024, 8:02:10 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

Taking everything into account, ARAV scores 2 out of 10 in our fundamental rating. ARAV was compared to 521 industry peers in the Biotechnology industry. While ARAV seems to be doing ok healthwise, there are quite some concerns on its profitability. ARAV does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • ARAV had negative earnings in the past year.
  • ARAV had a negative operating cash flow in the past year.
ARAV Yearly Net Income VS EBIT VS OCF VS FCFARAV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 -20M -40M -60M -80M -100M

1.2 Ratios

  • ARAV has a worse Return On Assets (-306.54%) than 96.29% of its industry peers.
  • ARAV's Return On Equity of -2344.12% is on the low side compared to the rest of the industry. ARAV is outperformed by 86.85% of its industry peers.
Industry RankSector Rank
ROA -306.54%
ROE -2344.12%
ROIC N/A
ROA(3y)-75.18%
ROA(5y)-71.51%
ROE(3y)-289.85%
ROE(5y)-204.67%
ROIC(3y)N/A
ROIC(5y)N/A
ARAV Yearly ROA, ROE, ROICARAV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 -200 -400 -600

1.3 Margins

  • ARAV does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ARAV Yearly Profit, Operating, Gross MarginsARAV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 -1K -2K -3K -4K -5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • ARAV does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for ARAV has been increased compared to 1 year ago.
  • There is no outstanding debt for ARAV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ARAV Yearly Shares OutstandingARAV Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M 50M
ARAV Yearly Total Debt VS Total AssetsARAV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M 200M

2.2 Solvency

  • ARAV has an Altman-Z score of -81.87. This is a bad value and indicates that ARAV is not financially healthy and even has some risk of bankruptcy.
  • With a Altman-Z score value of -81.87, ARAV is not doing good in the industry: 98.99% of the companies in the same industry are doing better.
  • There is no outstanding debt for ARAV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -81.87
ROIC/WACCN/A
WACC10.5%
ARAV Yearly LT Debt VS Equity VS FCFARAV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 50M -50M 100M -100M 150M

2.3 Liquidity

  • ARAV has a Current Ratio of 0.98. This is a bad value and indicates that ARAV is not financially healthy enough and could expect problems in meeting its short term obligations.
  • The Current ratio of ARAV (0.98) is worse than 90.56% of its industry peers.
  • ARAV has a Quick Ratio of 0.98. This is a bad value and indicates that ARAV is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 0.98, ARAV is doing worse than 89.38% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.98
Quick Ratio 0.98
ARAV Yearly Current Assets VS Current LiabilitesARAV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • ARAV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 59.32%, which is quite impressive.
  • ARAV shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -19.28%.
  • The Revenue for ARAV have been decreasing by -25.56% on average. This is quite bad
EPS 1Y (TTM)59.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%154.9%
Revenue 1Y (TTM)-19.28%
Revenue growth 3Y24.38%
Revenue growth 5Y-25.56%
Sales Q2Q%-44.35%

3.2 Future

  • ARAV is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.50% yearly.
  • ARAV is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -21.62% yearly.
EPS Next Y90.73%
EPS Next 2Y39.94%
EPS Next 3Y25.99%
EPS Next 5Y10.5%
Revenue Next Year-38.62%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-21.62%

3.3 Evolution

  • The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
ARAV Yearly Revenue VS EstimatesARAV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2026 2027 2028 2029 2030 0 0 0 0 0
ARAV Yearly EPS VS EstimatesARAV Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2019 2020 2021 2022 2023 2024 2026 2027 2028 2029 2030 0 -5 -10 -15 -20

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ARAV. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ARAV. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ARAV Price Earnings VS Forward Price EarningsARAV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ARAV Per share dataARAV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6 -0.8

4.3 Compensation for Growth

  • ARAV's earnings are expected to grow with 25.99% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.94%
EPS Next 3Y25.99%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for ARAV!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

Aravive Inc

NASDAQ:ARAV (1/26/2024, 8:02:10 PM)

After market: 0.042 +0 (+4.74%)

0.0401

-0.01 (-13.39%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-09
Earnings (Next)03-13
Inst Owners0.01%
Inst Owner Change0.27%
Ins Owners5.52%
Ins Owner Change0%
Market Cap2.95M
Revenue(TTM)6.99M
Net Income(TTM)-39.85M
Analysts43.33
Price Target0.26 (548.38%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)210.2%
Min EPS beat(2)58.96%
Max EPS beat(2)361.44%
EPS beat(4)2
Avg EPS beat(4)66.57%
Min EPS beat(4)-103.8%
Max EPS beat(4)361.44%
EPS beat(8)3
Avg EPS beat(8)34.04%
EPS beat(12)6
Avg EPS beat(12)27.35%
EPS beat(16)8
Avg EPS beat(16)14.94%
Revenue beat(2)2
Avg Revenue beat(2)584.84%
Min Revenue beat(2)187.33%
Max Revenue beat(2)982.35%
Revenue beat(4)4
Avg Revenue beat(4)384.65%
Min Revenue beat(4)125.18%
Max Revenue beat(4)982.35%
Revenue beat(8)7
Avg Revenue beat(8)250.15%
Revenue beat(12)10
Avg Revenue beat(12)281.52%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-23.08%
EPS NY rev (1m)0%
EPS NY rev (3m)67.21%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)0%
Revenue NY rev (3m)57.14%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.42
P/FCF N/A
P/OCF N/A
P/B 1.74
P/tB 1.74
EV/EBITDA N/A
EPS(TTM)-0.96
EYN/A
EPS(NY)-0.09
Fwd EYN/A
FCF(TTM)-0.81
FCFYN/A
OCF(TTM)-0.81
OCFYN/A
SpS0.1
BVpS0.02
TBVpS0.02
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -306.54%
ROE -2344.12%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-75.18%
ROA(5y)-71.51%
ROE(3y)-289.85%
ROE(5y)-204.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.54
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.98
Quick Ratio 0.98
Altman-Z -81.87
F-Score3
WACC10.5%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)59.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%154.9%
EPS Next Y90.73%
EPS Next 2Y39.94%
EPS Next 3Y25.99%
EPS Next 5Y10.5%
Revenue 1Y (TTM)-19.28%
Revenue growth 3Y24.38%
Revenue growth 5Y-25.56%
Sales Q2Q%-44.35%
Revenue Next Year-38.62%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-21.62%
EBIT growth 1Y8.31%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-13.95%
EBIT Next 3Y2.34%
EBIT Next 5Y-6.26%
FCF growth 1Y-203.26%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-203.21%
OCF growth 3YN/A
OCF growth 5YN/A

Aravive Inc / ARAV FAQ

What is the ChartMill fundamental rating of Aravive Inc (ARAV) stock?

ChartMill assigns a fundamental rating of 2 / 10 to ARAV.


Can you provide the valuation status for Aravive Inc?

ChartMill assigns a valuation rating of 1 / 10 to Aravive Inc (ARAV). This can be considered as Overvalued.


What is the profitability of ARAV stock?

Aravive Inc (ARAV) has a profitability rating of 0 / 10.